Exploratory Study of Iocide Oral Rinse in a Diabetic Population (Diabetes)
Exploratory Study of Iocide Oral Rinse in a Diabetic Population (Diabetes)
December 2008
ClinicalTrials.gov
This study is currently recruiting participants.
Verified by Biomedical Development Corporation, December 2008
Sponsors and Collaborators: Biomedical Development Corporation
Methodist Healthcare Ministries of South Texas
Foundation Of Collaborative Unique Science (FOCUS)
Information provided by: Biomedical Development Corporation
ClinicalTrials.gov Identifier: NCT00801164
Purpose
The goals of this exploratory study are to 1)examine an investigational oral rinse as an adjunctive agent to scaling and root planing in treating chronic periodontitis in a periodontitis-susceptible diabetes population, and 2) evaluate its effect on glycemic control and biomarkers of systemic inflammation.
Condition Intervention Phase
Diabetes Type 2
Periodontitis
Drug: Frio Mouth Rinse Placebo
Drug: Frio Mouth Rinse
Phase I
MedlinePlus related topics: Diabetes
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Exploratory Study of Iocide Oral Rinse in a Diabetic Population
Further study details as provided by Biomedical Development Corporation:
Primary Outcome Measures:
The primary study endpoints are periodontal evaluation including clinical attachment level, pocket depth, plaque index, suppuration and gingival index score. [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
Secondary endpoints include glycated hemoglobin A1c (HbA1c) and systemic biomarkers (LPS, TNF-a, CRP, IL-6, serum insulin and glucose). Tertiary outcome measures include staining, calculus, opportunistic Candida infection, and patient satisfaction. [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 30
Study Start Date: December 2008
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Frio Oral Rinse: Experimental
Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate. Drug: Frio Mouth Rinse
Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Placebo: Experimental
Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate. Drug: Frio Mouth Rinse Placebo
Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Detailed Description:
This double-blind prospective pilot study will evaluate the effects of an investigational oral rinse as an adjunctive agent to non-surgical periodontal intervention for patients with type 2 diabetes mellitus. Approximately thirty (30) adult (35 years or older) patients with type 2 diabetes mellitus with untreated chronic periodontitis of moderate or worse severity will be enrolled in the 6-month study to provide 24 evaluable subjects (12 per group). All subjects enrolled in the trial will receive standard periodontal therapy including scaling and root planing (SRP). Half will be randomized to receive the investigational oral rinse adjunctively twice daily; the other half will receive placebo rinse twice daily. Study participants will be treated with either Iocide or placebo rinse for the first 90 days of the study only. Follow up examinations will be performed at six months. Evaluation of biological markers associated with systemic inflammation and diabetes will be performed at baseline, three months, and six months. The primary study outcome is clinical measurement of chronic periodontitis (gingival index, bleeding on probing, probing depth, clinical attachment level). Secondary outcomes are change in HbA1c and markers of systemic inflammation measured by serum C-reactive protein, plasma TNF-a, and IL-6.
Eligibility
Ages Eligible for Study: 35 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
Criteria
Inclusion Criteria:
Have self-reported type 2 diabetes of more than three months duration.
A current HbA1c value between 7.5% and 12%.
Report no change in diabetes-related medications during the three months prior to enrollment.
Be at least 35 years of age.
Have at least 16 natural teeth, including at least 1 molar in 2 quadrants.
Have moderate to severe chronic periodontitis, defined by loss of clinical attachment of >4 mm in at least 8 sites (6 sites per tooth), and no treatment within six months.
Able and willing to comply with study requirements including following instructions on study treatment and returning for follow-up visits as required by the protocol
Have full understanding of all elements of, and signature and dating of the written informed consent prior to the initiation of protocol specified procedures
Females with childbearing potential must have a negative pregnancy test before and during the study period. Sexually active females must be using an effective form of birth control. These methods include oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrol implants (Norplant®), medroxyprogesterone acetate injections (Depo-provera®) or contraceptive foam with a condom.
Exclusion Criteria:
History, or current evidence, of any significant acute or chronic medical or psychiatric condition that, in the opinion of the Investigator, would render examination difficult or invalid or prevent the subject from active study participation
TPOab positive
Baseline serum level of TSH <0.35 or >5.5
Treatment with antibiotic within the three (3) month period prior to the screening examination
Presence of valvular disease, prosthetic implant, or any other systemic condition requiring antibiotic premedication
History of thyroid disease
Purported sensitivity or allergy to iodine
Known sensitivity or allergy to shellfish
History of autoimmune disease, or chronic infections such as HIV or hepatitis
History of cardiovascular disease (heart attack or procedure within the past three months, stroke or history/treatment for transient ischemic attacks in the past three months, or documented history of pulmonary embolus in past six months), unstable angina pectoris or angina pectoris at rest,
History of renal disease: serum creatinine exceeding 1.4 mg/dl (women) or 1.5 mg/dl (men), or currently receiving dialysis.
Gross oral pathology (periodontal disease, rampant caries, tissue damage created by poor oral care or treatment, soft or hard tissue tumors) that, in the opinion of the Investigator, could alter the treatment needs during the study
Current signs or symptoms of mucosal tissue ulcerations or inflammation, or canker sores
Presence of orthodontic appliances or any removable appliance that impinges on the oral tissues being assessed
History of or current alcohol abuse that, in the opinion of the Investigator, could influence the outcome of the study
History of, or current drug abuse
Use of concomitant medication that, in the opinion of the Investigator, might interfere with the outcome of the study (e.g. antibiotics, immuno-suppressants, steroids, or therapeutic doses of non-steroidal anti-inflammatory agents, phenytoin, calcium antagonists, cyclosporine or coumadin)
Concomitant therapy with another investigational drug or device without prior approval from the Sponsor within four weeks prior to Visit 2 (Study Day 1)
Concomitant endodontic or periodontal therapy other than prophylaxis in the past six (6) months
Females with childbearing potential with a positive pregnancy test, pregnant or nursing mothers, suspected pregnancy, or intention to become pregnant during the study
Residence in the same household as a subject already enrolled in the study (inclusion may create blinding and/or compliance issues)
Unable and unwilling to comply with the informed consent process, to meet study requirements including following instructions on study treatment, and to return for follow-up visits as required by the protocol.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00801164
Contacts
Contact: Thomas W. Oates, Jr., DMD, Ph.D. 210-567-3590
Contact: Jeremiah B. Cook, DDS 210-567-3329 cookjb@uthscsa.edu
Locations
United States, Texas
The University of Texas Health Science Center at San Antonio, Dental School Recruiting
San Antonio, Texas, United States, 78229
Contact: Thomas W. Oates, Jr., DMD, Ph.D. 210-567-3590 oates@uthscsa.edu
Contact: Jeremiah B. Cook, DDS 210-567-3329 cookjb@uthscsa.edu
Principal Investigator: Thomas W. Oates, DMD, Ph.D.
Sponsors and Collaborators
Biomedical Development Corporation
Methodist Healthcare Ministries of South Texas
Foundation Of Collaborative Unique Science (FOCUS)
Investigators
Principal Investigator: Thomas W. Oates, DMD, Ph.D. UTHSCSA
More Information
Responsible Party: UTHSCSA ( Thomas Oates, Jr., D.M.D., Ph.D. )
Study ID Numbers: HSC20080508H
First Received: December 2, 2008
Last Updated: December 2, 2008
ClinicalTrials.gov Identifier: NCT00801164
Health Authority: United States: Food and Drug Administration
Keywords provided by Biomedical Development Corporation:
Diabetes Type 2
Periodontitis
Study placed in the following topic categories:
Mouth Diseases
Periodontal Diseases
Metabolic Diseases
Periodontitis
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Stomatognathic Diseases
Metabolic disorder
Glucose Metabolism Disorders
Votes:40
Comments: 0